Camblong Jurgi sold $507K of SOPH
Camblong Jurgi (Executive Chairman) sold 83,679 shares of SOPHiA GENETICS SA (SOPH) at an average of $6.06 ($5.87–$6.30, $0.51M total) across 5 trades over 2026-06-29 to 2026-06-30 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed open-market sale amount, share count, and the confirmation that it was executed under a Rule 10b5-1 plan.
Market read
This provides a fresh, time-stamped insider selling datapoint for SOPH, but no fundamental company update.
What to watch
Traders may over-weight insider sales; without changes to guidance, trials, or financing, the disclosure is mostly sentiment/positioning rather than a catalyst.
Background
The article is an SEC Form 4 insider transaction report for SOPHiA GENETICS, filed July 1, 2026.
Ticker impact
SOPHiA GENETICS insider Camblong Jurgi (Executive Chairman) sold ~$506.7K of SOPH shares via an open-market sale under a 10b5-1 plan.
Limited/short-lived impact; any move is likely sentiment-driven rather than fundamental.
The filing is a Form 4 detailing a pre-arranged 10b5-1 open-market sale with no accompanying operational or guidance change.
Market effects
No direct sector read-through; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may not signal reduced conviction; it can be mechanically scheduled.
Key entities
- issuerSOPHiA GENETICS SA
Subject of the Form 4 insider transaction; ticker SOPH.
- insiderCamblong Jurgi
Executive Chairman and director/officer who sold shares.
- trading mechanismRule 10b5-1 plan
Pre-arranged plan noted as Yes in the filing.
